Publication | Closed Access

Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)

Hematological MalignancyTumor BiologySwiss GroupMedicineAcute Myeloid LeukemiaImmunologyHematologyMyeloid NeoplasiaRadiation OncologyOncologyCell BiologyCancer ResearchAxl ExpressionHealth Sciences